- Conditions
- Gaucher Disease, Type 2
- Interventions
- LY3884961, Methylprednisolone, Sirolimus, Prednisone
- Genetic · Drug
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 0 Months to 24 Months
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Oakland, California • Minneapolis, Minnesota • New York, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson Disease, Gaucher Disease, Healthy, GBA Gene Mutation
- Interventions
- Biological Sample Collection
- Other
- Lead sponsor
- New York Stem Cell Foundation Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Parkinson Disease, Gaucher Disease
- Interventions
- Not listed
- Lead sponsor
- Lysosomal and Rare Disorders Research and Treatment Center, Inc.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Parkinson Disease, GBA Gene Mutation, Gaucher Disease
- Interventions
- PET scan, neuroQWERTY
- Diagnostic Test
- Lead sponsor
- Pacific Parkinson's Research Centre
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Parkinson Disease
- Interventions
- collection of LFPs
- Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Parkinson, Parkinson Disease, Genetic Predisposition, GBA Gene Mutation, Cognitive Decline
- Interventions
- Not listed
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Parkinson's Disease
- Interventions
- venglustat GZ/SAR402671, Placebo
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 10 more
- Conditions
- GBA1 Parkinson Disease
- Interventions
- gene therapy
- Drug
- Lead sponsor
- Capsida Biotherapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • New York, New York • Philadelphia, Pennsylvania + 2 more
- Conditions
- Parkinson Disease, LRRK2, GBA Gene Mutation
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Parkinson Disease
- Interventions
- LY3884961, Methylprednisolone, Sirolimus
- Biological · Drug
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Murrieta, California • Englewood, Colorado + 7 more